ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
ProMIS Neurosciences, Inc. announced successful results from its annual shareholder meeting held on June 30, 2021, where all resolutions were overwhelmingly approved. A total of 104,999,925 shares were represented, accounting for 34.32% of the outstanding shares. The company re-elected its board of directors, appointed PricewaterhouseCoopers LLP as the auditor, and authorized a stock option plan. ProMIS focuses on developing antibody therapeutics for neurodegenerative diseases including Alzheimer’s, ALS, and Parkinson's.
- All resolutions approved at the annual meeting, indicating strong shareholder support.
- Re-election of directors with over 75% approval, enhancing governance stability.
- Appointment of reputable auditor PricewaterhouseCoopers LLP.
- Authorization of a stock option plan to incentivize performance.
- None.
ProMIS' shareholders show overwhelming support for all resolutions
TORONTO and CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the voting results of the Corporation's annual meeting of shareholders held on June 30, 2021 in Vancouver, British Columbia, Canada (the "Meeting").
ProMIS Neurosciences is pleased to announce that all resolutions described in the Management Proxy Circular and placed before the Meeting were overwhelmingly approved by the shareholders. The total number of common shares represented by shareholders present by proxy at the meeting was 104,999,925, representing 34.32% of the Corporation's outstanding common shares.
"This year’s Annual Meeting marks the sixth anniversary of ProMIS Neurosciences," stated Eugene Williams, ProMIS Executive Chairman. "On behalf of the Board of Directors and the ProMIS management team I would like to sincerely thank our shareholders for their on-going support. We look forward to continued progress applying our unique technology platform to the development of disease-modifying antibody therapies, diagnostics and potential vaccines for neurodegenerative diseases, including Alzheimer’s, ALS and Parkinson’s disease."
In particular, the following are the voting results for the 103,137,426 common shares that were voted in person or by proxy at the Meeting.
1. The following directors were elected, with each nominee receiving a minimum majority of
| DIRECTOR | FOR | WITHHELD |
| Eugene Williams | 55,876,666 | 18,219,274 |
| Neil Cashman, M.D. | 73,388,087 | 707,853 |
| Richard J. Gregory, PH.D. | 67,464,866 | 6,631,074 |
| Patrick D. Kirwin | 67,364,166 | 6,731,744 |
| Neil K. Warma | 69,534,991 | 4,560,949 |
| William Wyman | 56,967,143 | 17,128,797 |
2. PricewaterhouseCoopers LLP, Chartered Professional Accountants, were appointed auditor of the Company and the Board authorized to fix the auditor’s remuneration. Shares voted in person and by proxies received represented 103,279,732 votes FOR and 1,720,193 votes WITHHELD.
3. The ordinary resolution to authorize the Corporation to grant options pursuant to the Corporation’s
About ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information about ProMIS Neurosciences, please consult the Company’s website at: www.promisneurosciences.com
Follow us on Twitter, Like us on LinkedIn
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What were the results of ProMIS Neurosciences' annual meeting on June 30, 2021?
What percentage of shares were represented at ProMIS Neurosciences' annual meeting?
Who was appointed as the auditor for ProMIS Neurosciences?
What focus areas does ProMIS Neurosciences specialize in?
What is the stock symbol for ProMIS Neurosciences on the OTCQB?
